109 related articles for article (PubMed ID: 35714939)
1. Serum immunoinflammatory-related protein complexes as personalized biomarkers for monitoring disease progression and response to treatment in lung cancer patients.
Zhang H; Li D; Lai Z; Zhou J; Zhang J; Li Z
Clin Chim Acta; 2022 Aug; 533():53-62. PubMed ID: 35714939
[TBL] [Abstract][Full Text] [Related]
2. Personalized biomarkers to monitor disease progression in advanced non-small-cell lung cancer patients treated with icotinib.
Song G; Liu Y; Wang Y; Ren G; Guo S; Ren J; Zhang L; Li Z
Clin Chim Acta; 2015 Feb; 440():44-8. PubMed ID: 25447696
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum levels of circulating immunoinflammation-related protein complexes are associated with cancer.
Wang Y; Song G; Wang Y; Qiu L; Qin X; Liu H; Li F; Wang X; Li F; Guo S; Zhang Y; Li Z
J Proteome Res; 2014 Feb; 13(2):710-9. PubMed ID: 24295561
[TBL] [Abstract][Full Text] [Related]
4. Serum immunoinflammation-related protein complexes discriminate between inflammatory bowel disease and colorectal cancer.
Sun YH; Li J; Shu HJ; Li ZL; Qian JM
Clin Transl Oncol; 2019 Dec; 21(12):1680-1686. PubMed ID: 30955196
[TBL] [Abstract][Full Text] [Related]
5. Increased Levels of Serum Protein Complexes Are Associated with Type 2 Diabetes.
Liu Y; Wu Y; Wang Y; Zhang M; Li Z
Int J Med Sci; 2018; 15(3):210-216. PubMed ID: 29483811
[No Abstract] [Full Text] [Related]
6. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
[TBL] [Abstract][Full Text] [Related]
7. Case Report: Exploration of changes in serum immunoinflammation-related protein complexes of patients with metastatic breast cancer.
Chen C; Xu Y; Lai Z; Li Z; Sun Q
Front Oncol; 2023; 13():1207991. PubMed ID: 37546392
[TBL] [Abstract][Full Text] [Related]
8. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
[TBL] [Abstract][Full Text] [Related]
9. Circulating biomarkers for monitoring therapy response and detection of disease progression in lung cancer patients.
de Kock R; Borne BVD; Soud MY; Belderbos H; Stege G; de Saegher M; van Dongen-Schrover C; Genet S; Brunsveld L; Scharnhorst V; Deiman B
Cancer Treat Res Commun; 2021; 28():100410. PubMed ID: 34107412
[TBL] [Abstract][Full Text] [Related]
10. Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung.
Muley T; He Y; Rolny V; Wehnl B; Escherich A; Warth A; Stolp C; Schneider MA; Meister M; Herth FJ; Dayyani F
Lung Cancer; 2019 Apr; 130():194-200. PubMed ID: 30885344
[TBL] [Abstract][Full Text] [Related]
11. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
Li N; Wang BX; Li J; Shao Y; Li MT; Li JJ; Kuang PP; Liu Z; Sun TY; Wu HQ; Ou W; Wang SY
Cancer; 2022 Feb; 128(4):708-718. PubMed ID: 35076939
[TBL] [Abstract][Full Text] [Related]
12. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
13. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
Redman MW; Papadimitrakopoulou VA; Minichiello K; Hirsch FR; Mack PC; Schwartz LH; Vokes E; Ramalingam S; Leighl N; Bradley J; Miao J; Moon J; Highleyman L; Miwa C; LeBlanc ML; Malik S; Miller VA; Sigal EV; Adam S; Wholley D; Sigman C; Smolich B; Blanke CD; Kelly K; Gandara DR; Herbst RS
Lancet Oncol; 2020 Dec; 21(12):1589-1601. PubMed ID: 33125909
[TBL] [Abstract][Full Text] [Related]
14. The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer.
Shibata Y; Kobayashi N; Sato T; Nakashima K; Kaneko T
Thorac Cancer; 2020 May; 11(5):1258-1264. PubMed ID: 32163231
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum immunoinflammation-related protein complexes are associated with psychosis.
Liu Y; Zhang D; Cheng Y; Li Z
Psychiatry Res; 2015 Nov; 230(1):96-101. PubMed ID: 26337482
[TBL] [Abstract][Full Text] [Related]
16. Presence of podoplanin-positive cancer-associated fibroblasts in surgically resected primary lung adenocarcinoma predicts a shorter progression-free survival period in patients with recurrences who received platinum-based chemotherapy.
Koriyama H; Ishii G; Yoh K; Neri S; Morise M; Umemura S; Matsumoto S; Niho S; Ohmatsu H; Tsuboi M; Goto K; Ochiai A
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1163-70. PubMed ID: 25446816
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal serum autoantibody repertoire profiling identifies surgery-associated biomarkers in lung adenocarcinoma.
Li Y; Li CQ; Guo SJ; Guo W; Jiang HW; Li HC; Tao SC
EBioMedicine; 2020 Mar; 53():102674. PubMed ID: 32113159
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-486 as a Biomarker for Early Diagnosis and Recurrence of Non-Small Cell Lung Cancer.
Li W; Wang Y; Zhang Q; Tang L; Liu X; Dai Y; Xiao L; Huang S; Chen L; Guo Z; Lu J; Yuan K
PLoS One; 2015; 10(8):e0134220. PubMed ID: 26237047
[TBL] [Abstract][Full Text] [Related]
19. Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening.
Sestini S; Boeri M; Marchiano A; Pelosi G; Galeone C; Verri C; Suatoni P; Sverzellati N; La Vecchia C; Sozzi G; Pastorino U
Oncotarget; 2015 Oct; 6(32):32868-77. PubMed ID: 26451608
[TBL] [Abstract][Full Text] [Related]
20. Serum immune modulators during the first cycle of anti-PD-1 antibody therapy in non-small cell lung cancer: Perforin as a biomarker.
Ota T; Fukui T; Nakahara Y; Takeda T; Uchino J; Mouri T; Kudo K; Nakajima S; Suzumura T; Fukuoka M
Thorac Cancer; 2020 Nov; 11(11):3223-3233. PubMed ID: 32915511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
